Vincent Lo Re
Assistant Professor of Medicine
Attending Physician, Infectious Diseases Section, Medicine Service, Philadelphia Veterans Affairs Medical Center
Attending Physician, Infectious Diseases Division, Penn Presbyterian Medical Center
Senior Scholar, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
Attending Physician, Center for Viral Hepatitis, Perelman School of Medicine, University of Pennsylvania
Department: Medicine
Contact information
Center for Clinical Epidemiology and Biostatistics
836 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
836 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
Office: 215-573-5964
Fax: 215-349-5111
Fax: 215-349-5111
Email:
vincentl@mail.med.upenn.edu
vincentl@mail.med.upenn.edu
Graduate Group Affiliations
Publications
Education:
B.S. (Chemistry)
Georgetown University, 1992.
M.D. (Medicine)
University of Pennsylvania, 1997.
M.S.C.E. (Pharmacoepidemiology)
University of Pennsylvania, 2005.
B.S. (Chemistry)
Georgetown University, 1992.
M.D. (Medicine)
University of Pennsylvania, 1997.
M.S.C.E. (Pharmacoepidemiology)
University of Pennsylvania, 2005.
Links
Search PubMed for articles
Center for Clinical Epidemiology and Biostatistics faculty webpage.
Permanent linkSearch PubMed for articles
Center for Clinical Epidemiology and Biostatistics faculty webpage.
Description of Research Expertise
Research Interests- Hepatic and non-hepatic outcomes of chronic hepatitis B and C, particularly among patients with HIV infection
- Adherence to hepatitis C virus therapy
- Hepatotoxicity of medications
- Evaluation of clinical outcomes
- Population-based and administrative databases
Key Words
HIV/viral hepatitis coinfection; hepatitis B; hepatitis C; HIV/AIDS; epidemiology; clinical outcomes; pharmacoepidemiology
Description of Research
Dr. Lo Re’s research focuses on clinical outcomes of chronic viral hepatitis infection in HIV-infected patients. He is conducting epidemiologic studies to examine novel risk factors for decompensated cirrhosis among HIV/hepatitis C-coinfected patients and is working to develop and internally validate a clinical predictive index to stratify HIV/hepatitis C patients according to their risk of progression to hepatic decompensation. He has also examined the prevalence, risk factors, and clinical significance of occult hepatitis B virus infection in HIV-infected patients. Additional studies are examining non-hepatic outcomes of chronic viral hepatitis infection in HIV, particularly abnormalities in bone mineral density and fractures.
Dr. Lo Re also evaluates clinical outcomes of hepatitis therapy in the setting of HIV. Recent work has examined the incidence and risks factors for anemia and weight loss during hepatitis C therapy among HIV-infected patients. Another active area of research is adherence to combination pegylated interferon and ribavirin hepatitis C therapy, specifically examining the levels of adherence required for maximal hepatitis C suppression and risk factors for poor adherence to these therapies.
Methodologic interests include use of population-based databases for epidemiologic research, ascertainment and adjudication of clinical outcomes, and pharmacoepidemiology.
Description of Itmat Expertise
Dr. Lo Re is an infectious diseases physician and clinical epidemiologist whose area of interest is the epidemiology of chronic viral hepatitis, HIV/viral hepatitis co-infection, and drug-induced liver injury.Selected Publications
Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd: Incidence and risk factors for incomplete hepatitis B virus DNA suppression in HIV/hepatitis B-coinfected patients receiving tenofovir-based antiretroviral therapy. J Viral Hepat Page: In Press, June 2013.Amorosa VK, Aibana O, Shire NJ, Dorey-Stein Z, Ferrara T, Gilmore J, Kostman JR, Lo Re V 3rd: Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients. J Clin Gastroenterol 47: 457-60, June 2013.
Edelman EJ, Gordon K, Lo Re V III, Skanderson M, Fiellin DA, Justice AC: Acetaminophen receipt among HIV-infected patients with advanced hepatic fibrosis. Society of General Internal Medicine 36th Annual Meeting. Denver, CO [Abstract 1640956]. April 24 – 27, 2013.
Tetrault J, Tate J, Edelman EJ, Gordon A, Lo Re V III, Fiellin L, Bryant K, Justice A, Fiellin DA: Use and safety of buprenorphine in HIV-infected and uninfected opioid dependent patients. Society of General Internal Medicine 36th Annual Meeting. Denver, CO [Abstract 1640823]. April 24 – 27, 2013.
Lo Re V III, Kallan M, Tate J, Localio AR, Lim JK, Goetz MB, Butt AA, Brown ST, Kostman JR, Justice AC: Determinants of hepatic decompensation in ARV-treated HIV/HCV-coinfected patients. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA [Abstract 728]. March 3-6, 2013.
Armah KA, Lim JK, Lo Re V III, Baker JV, Tracy RP, Butt AA, Agan BK, Rimland D, Justice AC, Freiberg MS: HIV seroconversion, ART initiation, and changes in biomarkers of end-organ disease and function. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA [Abstract 782]. March 3-6, 2013.
Goldberg DS, Lewis JD, Halpern SD, Weiner M, Lo Re V 3rd: Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database. Pharmacoepidemiol Drug Saf 22(1): 103-7, Jan 2013.
Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R: Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients. AIDS Behav 17(1): 94-103, Jan 2013.
Raphael BA, Dorey-Stein ZL, Lott J, Amorosa VK, Lo Re V 3rd, Kovarik C: Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection. J Am Acad Dermatol 67: 962-8, Nov 2012.
Lo Re V 3rd, Haynes K, Ming EE, Wood Ives J, Horne LN, Fortier K, Carbonari DM, Hennessy S, Cardillo S, Reese PP, Reddy KR, Margolis D, Apter A, Kimmel SE, Roy J, Freeman CP, Razzaghi H, Holick CN, Esposito DB, Van Staa TP, Bhullar, H, Strom BL: Safety of saxagliptin: Rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf 21: 1202-15, Nov 2012.